Stephens cut shares of Cerus (NASDAQ:CERS – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Tuesday, MarketBeat reports. They currently have $3.75 price target on the biotechnology company’s stock.
Several other equities research analysts have also recently weighed in on CERS. Cantor Fitzgerald reaffirmed an overweight rating on shares of Cerus in a research report on Monday, December 5th. StockNews.com assumed coverage on shares of Cerus in a research report on Wednesday, October 12th. They set a hold rating for the company. Finally, BTIG Research cut their price objective on shares of Cerus to $6.00 in a research report on Tuesday, November 15th.
Cerus Stock Performance
Shares of Cerus stock opened at $3.14 on Tuesday. The firm has a 50-day moving average of $3.75 and a 200-day moving average of $4.19. The stock has a market cap of $557.10 million, a PE ratio of -14.27 and a beta of 1.09. Cerus has a 52-week low of $2.53 and a 52-week high of $6.00. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.73.
Insiders Place Their Bets
In other Cerus news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business’s stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $3.91, for a total transaction of $48,875.00. Following the completion of the transaction, the director now owns 113,808 shares of the company’s stock, valued at $444,989.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.33% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Sepio Capital LP increased its stake in shares of Cerus by 0.4% in the second quarter. Sepio Capital LP now owns 520,715 shares of the biotechnology company’s stock valued at $1,495,000 after buying an additional 2,200 shares during the period. Mackenzie Financial Corp boosted its holdings in Cerus by 3.0% in the second quarter. Mackenzie Financial Corp now owns 78,624 shares of the biotechnology company’s stock valued at $416,000 after acquiring an additional 2,264 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in Cerus by 3.3% in the second quarter. Los Angeles Capital Management LLC now owns 81,213 shares of the biotechnology company’s stock valued at $430,000 after acquiring an additional 2,600 shares during the last quarter. Bouvel Investment Partners LLC boosted its holdings in Cerus by 1.4% in the second quarter. Bouvel Investment Partners LLC now owns 214,503 shares of the biotechnology company’s stock valued at $1,135,000 after acquiring an additional 3,008 shares during the last quarter. Finally, Algert Global LLC boosted its holdings in Cerus by 1.5% in the third quarter. Algert Global LLC now owns 263,790 shares of the biotechnology company’s stock valued at $950,000 after acquiring an additional 3,782 shares during the last quarter. Institutional investors and hedge funds own 82.47% of the company’s stock.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- Get a free copy of the StockNews.com research report on Cerus (CERS)
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Thor Industries Hammered Its Numbers. Is it a Buy?
- Tritium Is the Largest DC EV Charger Maker You’ve Never Heard Of
- United Airlines Soars Ahead of Earnings…Time to Deplane?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.